- Patients
- Clinical Research
- Clinical trials
- Rag-01-01
2024-08-28T05:38:09.563Z
Rag-01-01
Rag-01-01
Bladder cancer
A phase I, single-arm, open label, multicenter, first-in-human trail to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with non-muscle invasive bladder cancer (NMIBC) who have failed Bacillus Calmette Guerin (BCG) therapy.
A phase I, single-arm, open label, multicenter, first-in-human trail to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with non-muscle invasive bladder cancer (NMIBC) who have failed Bacillus Calmette Guerin (BCG) therapy.
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Bladder cancer
Study Phase
I
Trial Identifiers
GenesisCare Location(s)
GenesisCare North Shore
GenesisCare North Shore
:::
Principal Investigator(s)